Ypsomed Holding AG (YPSN) Earnings Call Transcript & Summary

Dear shareholders and partners, at Ypsomed, we can look back on another successful year. In Delivery Systems, we achieved a record result with our pens and autoinjectors. In pens, we are proud to be making an important contribution to access to affordable insulin with several significant collaborations in this space. In autoinjectors, the YpsoMate 2.25 for large volumes, in particular, achieved very strong sales growth. And based on our partnerships with Abbott, Dexcom and CamDiab, we are finally achieving satisfying results in our Diabetes Care business as well. We were able to more than double commercial sales of our YpsoPump business last year. And we are excited to significantly improve life for people with diabetes with our mylife Loop AID solution that enables users to benefit from a unique and adaptive algorithm that runs on smartphones. We exceeded the interim target of 30,000 active pump users at the end of the financial year and see a clear path towards profitability in our pump business. So what's next? New business acquisition in Delivery Systems continues to ensure our further growth potential. And at the same time, we are pressing ahead with the expansion of our portfolio and capacity. For example, adding the even large volume, YpsoMate 5.5, which enables the use of new drugs in selfcare, expanding our portfolio with innovative services in the area of sustainability and building large capacity for our record-breaking autoinjector business by the end of the decade. And in Diabetes Care, well, we are adding features and functions on a regular basis, such as the Companion app for parents to follow their kids while at school or the iOS version for our smartphone control or our continued push towards U.S. market entry. In the past year, we have also put a strong focus on our ambitious climate program. We have defined very concrete emission reduction targets across the entire value chain and submitted them to the Science Based Targets initiative. In the space of sustainability, we clearly see ourselves in a pioneering role for our industry. With a record investment budget of over CHF 200 million, we are moving further and are investing even more than ever in innovation and capacity expansion. And by adding over 300 new colleagues, we ensure our top line growth targets. I would like to thank all employees who worked tirelessly for the well-being of people with chronic conditions and have contributed to our success. Join us on this journey.